Skip to main content

Niven Ralph's Form 4 filing

Jade Biosciences, Inc. (JBIO) · filed Feb 7, 2024

Accession no.
0001415889-24-002957
Filed
Feb 7, 2024
Trade date
Feb 5, 2024
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions and 5 derivative transactions. Open-market sales total $80.3K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Niven RalphCIK 0001168060Officer (CHIEF SCIENTIFIC OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 5, 2024Common StockMOption exerciseAcquired+1,400$1.74+$2,4363,009Direct
Feb 5, 2024Common StockMOption exerciseAcquired+3,200$2.14+$6,8486,209Direct
Feb 5, 2024Common StockSSaleDisposed−4,600$17.45−$80,2701,609Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 5, 2024Common StockMOption exerciseDisposed−900$0.00$013,308Direct
Feb 5, 2024Common StockMOption exerciseDisposed−500$0.00$09,088Direct
Feb 5, 2024Common StockMOption exerciseDisposed−500$0.00$010,894Direct
Feb 5, 2024Common StockMOption exerciseDisposed−1,200$0.00$034,908Direct
Feb 5, 2024Common StockMOption exerciseDisposed−1,500$0.00$041,732Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)